Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis
Status:
Recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
To study the efficacy and safety of combination of Ro-Peg-interferon-α2b (RoPegIFN) with
Bosutinib (BOS) in comparison to BOS monotherapy, as frontline therapy for newly diagnosed
chronic myeloid leukemia patients, and to estimate efficacy of the addition of RoPegIFN to
BOS in terms of deep molecular response with the aim of increasing the proportion of patients
who may achieve treatment free remission. (NCMLSG study #NordCML012)
Phase:
Phase 2
Details
Lead Sponsor:
St. Olavs Hospital
Collaborators:
Haukeland University Hospital Helse Stavanger HF Henri Mondor University Hospital Hôpital Mignot, Versailles Paris Hôpital René Huguenin Odense University Hospital Oslo University Hospital University Hospital of North Norway Uppsala University Hospital